Biosimilars vs originators: Are they the same?

Piercarlo Sarzi-Puttini, Daniela Marotto, Roberto Caporali, Mauro Galeazzi, Fabiola Atzeni, Attila Hamar, Boglárka Soós, Zoltán Szekanecz

Research output: Contribution to journalArticlepeer-review


Biological drugs have revolutionised the treatment of rheumatic diseases, and the recent expiry of the patents for many biological agents has generated considerable interest among pharmaceutical companies and regulatory agencies, and led to the marketing of highly similar, low-cost versions known as biosimilars. The increasing trend of switching patients from effective but expensive drugs to their biosimilar counterparts will have a considerable economic impact in the coming years. However, although this will greatly extend patient access the latest treatments, clinicians, scientific societies and the patients themselves have expressed a number of concerns about their long-term efficacy and safety, as well as the consequences of potentially multiple switches being dictated by economic pressure rather than medical needs. Thee aim of this review is to evaluate the pros and cons of choosing biosimilars, and whether and when they can really be considered clinically equivalent to the original drugs.
Original languageEnglish
Pages (from-to)102404
Number of pages1
JournalAutoimmunity Reviews
Issue number12
Publication statusPublished - Dec 2019


  • Biosimilars
  • Extrapolation
  • Interchangeability
  • Originators
  • Switching
  • Antirheumatic Agents/therapeutic use
  • Biosimilar Pharmaceuticals/*therapeutic use
  • Humans
  • Rheumatic Diseases/*drug therapy


Dive into the research topics of 'Biosimilars vs originators: Are they the same?'. Together they form a unique fingerprint.

Cite this